Trade Ideas

Actionable trade ideas with defined risk and time horizons.

Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.

Articles

2,845 total articles

CK Hutchison: Buy the Turnaround as Portfolio Moves Add Upside

CK Hutchison: Buy the Turnaround as Portfolio Moves Add Upside

CK Hutchison (CKHUY) offers a favorable risk/reward after management signaled portfolio rationalization and the operating picture across retail, telecom and infrastructure shows early signs of stabilization. At a market cap of roughly $28.7B, a sub-0.4 PB and a 3.06% yield, the stock is priced for disappointment. We upgrade to Buy and lay out an ac…

eBay: A Cheap Way to Play StubHub-Style Optionality

eBay: A Cheap Way to Play StubHub-Style Optionality

eBay at ~$88 looks materially undervalued relative to its cash flows, buyback cadence and strategic optionality. With free cash flow of $1.43B, a market cap near $40B and new growth engines (Depop acquisition, advertising nearing $2B, recommerce at 40% of GMV), the risk/reward favors a long trade. This idea frames a concrete entry at $88.50 with a …

Cooper-Standard: Buy the Business, Watch the Debt - Tactical Swing Trade

Cooper-Standard: Buy the Business, Watch the Debt - Tactical Swing Trade

Cooper-Standard (CPS) is a cyclical auto-parts supplier with improving cash flow and a reasonable valuation (P/E ~16, EV/EBITDA ~6.6). Recent refinancing terms are sub-optimal and increase near-term leverage risk, but the company's free cash flow generation and normalized margins support a tactical long swing. Entry $29.55, target $36.00, stop $26.…

Dave & Buster's: A Contrarian Setup, But Not Yet a Buy

Dave & Buster's: A Contrarian Setup, But Not Yet a Buy

PLAY has been hammered to a single-digit handle in the past year and now trades at an enterprise value that looks inexpensive versus sales and EBITDA. That creates a tempting contrarian scenario. Still, negative free cash flow, margin pressure and high short interest argue for caution. This trade idea outlines a disciplined entry if management can …

NextDecade Upgrade: A Tactical Long on LNG Re-Rationing

NextDecade Upgrade: A Tactical Long on LNG Re-Rationing

NextDecade (NEXT) has been re-priced by the market after a supply shock to global LNG and a string of project wins. The company remains pre-revenue but its Rio Grande LNG progress, a strong strategic investor base and a stretched short interest profile create a technical and fundamental setup for a mid-term swing. This is a tactical, higher-risk lo…

Why AMD Deserves an Upgrade: Tactical Long vs. Nvidia Into AI Cycle

Why AMD Deserves an Upgrade: Tactical Long vs. Nvidia Into AI Cycle

We upgrade AMD to a tactical long. The company combines improving AI GPU and datacenter CPU momentum, clean balance sheet and solid free cash flow that make a measured buy here attractive. Technicals and macro sentiment favor a recovery toward prior highs; we lay out entry at $205.00, stop at $185.00 and target at $260.00 for a mid-term swing (45 t…

Exxon Mobil: Tactical Long as Iran Conflict Sends Oil and Earnings Higher

Exxon Mobil: Tactical Long as Iran Conflict Sends Oil and Earnings Higher

Exxon Mobil (XOM) is the largest integrated oil company with low leverage, strong free cash flow and advantaged production in the Permian and Guyana. The recent Iran conflict has pushed global crude above $100/bbl, creating a clear upside to Exxon’s near-term earnings and cash generation. We lay out a tactical mid-term long with entry, stop and tar…

Buy the Dip: A Short Delay Could Improve Firmonertinib's Phase 3 Odds

Buy the Dip: A Short Delay Could Improve Firmonertinib's Phase 3 Odds

ArriVent BioPharma (AVBP) is a clinical-stage oncology name trading at roughly $22.34 with a market cap near $981M. Recent company activity - including AACR preclinical posters and a pivot into a global Phase 3 for firmonertinib - has created a binary investment case. If a short scheduling delay is used to refine endpoints, broaden inclusion criter…

You’re Up 150% On Planet Labs: Take Chips Off, Let the Core Ride

You’re Up 150% On Planet Labs: Take Chips Off, Let the Core Ride

Planet Labs (PL) has gone from a beaten-down name to one of 2025-26's high flyers. With Q4 revenue surprise, bullish guidance and AI/defense catalysts, the stock looks bid — but valuation and momentum leave little margin for error. This note lays out a concrete trade: harvest partial profits now, protect a core position with a trailing stop, and a …

Huntington Bancshares: Watching a Risk-Reward Setup Around $15.45

Huntington Bancshares: Watching a Risk-Reward Setup Around $15.45

Huntington (HBAN) trades near $15.45, a valuation that looks inexpensive relative to growth and free cash flow, while near-term catalysts (merger synergies, sector momentum, and dividend yield) could re-rate the stock. The trade below is a mid-term swing (45 trading days) long with a clear stop and target. This is not a blind buy — credit trends an…

Buy 10x Genomics on a Consumables Re-rate: Cheap FCF with Upside to $30

Buy 10x Genomics on a Consumables Re-rate: Cheap FCF with Upside to $30

10x Genomics (TXG) is an actionable long: the stock trades at a $2.45B market cap, is generating meaningful free cash flow ($130.1M trailing), and is moving toward a higher-margin, consumables-led revenue mix that should compress multiples and re-rate the shares. Technicals are neutral and short interest remains material, so use a defined entry and…